Current literature review on the tumor immune micro-environment, its heterogeneity and future perspectives in treatment of advanced non-small cell lung cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lim, Jeong Uk | - |
dc.contributor.author | Lee, Eunyoung | - |
dc.contributor.author | Lee, Sang-Yun | - |
dc.contributor.author | Cho, Hyeong Jun | - |
dc.contributor.author | Ahn, Dong Hyuck | - |
dc.contributor.author | Hwang, Yongki | - |
dc.contributor.author | Choi, Joon Young | - |
dc.contributor.author | Yeo, Chang Dong | - |
dc.contributor.author | Park, Chan Kwon | - |
dc.contributor.author | Kim, Seung Joon | - |
dc.date.accessioned | 2024-01-07T00:30:40Z | - |
dc.date.available | 2024-01-07T00:30:40Z | - |
dc.date.issued | 2023-04 | - |
dc.identifier.issn | 2218-6751 | - |
dc.identifier.issn | 2226-4477 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/89970 | - |
dc.description.abstract | Background and Objective: Immune checkpoint inhibitors (ICI) were a major clinical advancement that provided an opportunity to improve the prognosis of patients with non-small cell lung cancer (NSCLC). However, PD-L1 expression does not sufficiently predict ICI efficacy in NSCLC patients. In recent studies, the tumor immune microenvironment (TIME) was shown to have a central role in lung cancer progression and to affect clinical outcome of patients diagnosed with lung cancer. As development of new therapeutic targets to overcome ICI resistance is a priority, understanding the TIME is important. Recently, a series of studies was conducted to target each component of TIME to improve efficacy of cancer treatment. In this review, important features related to TIME, its heterogeneity and current trends in treatment targeting the component of TIME are discussed. Methods: PubMed and PMC were searched from January 1st, 2012 to August 16th, 2022 using the following key words: "NSCLC", "Tumor microenvironment", "Immune", "Metastasis" and "Heterogeneity" Key Content and Findings: Heterogeneity in the TIME can be either spatial or temporal. Subsequent to heterogeneous changes in the TIME, treatment of lung cancer can be more challenging because drug resistance is more likely to occur. In terms of the TIME, the main concept for increasing the chance of successful NSCLC treatment is to activate immune responses against tumor cells and inhibit immunosuppressive activities. In addition, relevant research is focused on normalizing an otherwise aberrant TIME in NSCLC patients. Potential therapeutic targets include immune cells, cytokine interactions, and non-immune cells such as fibroblasts or vessels. Conclusions: In management of lung cancer, understanding TIME and its heterogeneity is significant to treatment outcomes. Ongoing trials including various treatment modalities such as radiotherapy, cytotoxic chemotherapy, and anti-angiogenic treatment and regimens inhibiting other immunoinhibitory molecules are promising. | - |
dc.format.extent | 20 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | AME PUBLISHING COMPANY | - |
dc.title | Current literature review on the tumor immune micro-environment, its heterogeneity and future perspectives in treatment of advanced non-small cell lung cancer | - |
dc.type | Article | - |
dc.identifier.wosid | 000954815600001 | - |
dc.identifier.doi | 10.21037/tlcr-22-633 | - |
dc.identifier.bibliographicCitation | TRANSLATIONAL LUNG CANCER RESEARCH, v.12, no.4, pp 857 - 876 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.scopusid | 2-s2.0-85160305868 | - |
dc.citation.endPage | 876 | - |
dc.citation.startPage | 857 | - |
dc.citation.title | TRANSLATIONAL LUNG CANCER RESEARCH | - |
dc.citation.volume | 12 | - |
dc.citation.number | 4 | - |
dc.type.docType | Review | - |
dc.publisher.location | 중국 | - |
dc.subject.keywordAuthor | Tumor microenvironment | - |
dc.subject.keywordAuthor | immune | - |
dc.subject.keywordAuthor | heterogeneity | - |
dc.subject.keywordAuthor | non-small cell lung cancer (NSCLC) | - |
dc.subject.keywordAuthor | immunotherapy | - |
dc.subject.keywordPlus | REGULATORY T-CELLS | - |
dc.subject.keywordPlus | TERTIARY LYMPHOID STRUCTURES | - |
dc.subject.keywordPlus | BRAIN METASTASES | - |
dc.subject.keywordPlus | OPEN-LABEL | - |
dc.subject.keywordPlus | B-CELLS | - |
dc.subject.keywordPlus | SUPPRESSOR-CELLS | - |
dc.subject.keywordPlus | PROGNOSTIC VALUE | - |
dc.subject.keywordPlus | DENDRITIC CELLS | - |
dc.subject.keywordPlus | BONE-MARROW | - |
dc.subject.keywordPlus | TNF-ALPHA | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Respiratory System | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Respiratory System | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.